CRS 207

Drug Profile

CRS 207

Alternative Names: ANZ-207; Cancer vaccine - Aduro BioTech; CRS-207; Listeria monocytogenes-expressing mesothelin - Aduro Biotech

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cerus Corporation; Chugai Pharmaceutical; Johns Hopkins University
  • Developer Aduro BioTech; Merck AG
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Megakaryocyte potentiating factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastric cancer; Mesothelioma; Oesophageal cancer; Pancreatic cancer
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 18 Jun 2017 Sidney Kimmel Comprehensive Cancer Center, Bristol-Myers Squibb and Aduro Biotech plan the phase II trial for Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03190265)
  • 01 Jun 2017 Phase-II clinical trials in Mesothelioma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03175172)
  • 17 May 2017 Aduro Biotech and Merck plan a phase II trial for Mesothelioma (Combination therapy, Second-line therapy or greater)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top